Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 214, Issue 1-2, Pages 93-100Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2009.07.006
Keywords
CIDP; Guillain-Barre syndrome; S1P receptors; NOD mice; FTY720; SEW2871
Categories
Funding
- National Institute of Health Grant [R21 NS049014]
- Miller Group Charitable Trust Fund
- Jack Miller Center for Peripheral Neuropathy
- Novartis (Basel, Switzerland) [FTY720]
Ask authors/readers for more resources
We investigated potential therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators FTY720 (fingolimod) and selective S1P1 agonist SEW2871 on a spontaneous autoimmune polyneuropathy (SAP) when given orally at 7 mo (anticipated disease onset) for 4 weeks. Clinical severity, electrophysiologic and histological findings were ameliorated in mice treated with 1 mg/kg of FTY720. Subsequent studies showed that SEW2871 was also effective in halting the progression of SAP, which was accompanied by decreased proliferative and cytokine responses to myelin protein zero (P0), and an increase in regulatory T cells. We conclude that SIP receptor modulators may play a therapeutic role in autoimmune neuropathies. (c) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
